Using one scan to predict early scarred lung disease
Part of Lungs & breathing clinical trials.
This study uses a single lung scan to find early signs of progressive scarring (fibrosis) in people with pulmonary fibrosis. It may help doctors predict which patients will get worse faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pulmonary fibrosis (IPF or another type) in the last 5 years.
- You are 18 or older (or 40+ for IPF).
- Your lung function tests (FVC and DLCO) are above certain levels.
- You are not currently on the lung transplant list or planning to join a drug trial in the next 6 months.
- You have no recent or active cancer (some skin cancers are okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
This study uses lung tissue removed during lung transplant to learn more about lung scarring (pulmonary fibrosis). It can help researchers understand the disease better and improve future treatments.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This trial looks at different types of lung scarring (called interstitial lung disease) to better understand the condition across all ages. It also includes family members of people with certain genetic mutations that affect the lungs.
This study looks at people with a condition called idiopathic pulmonary fibrosis (IPF), which causes lung scarring. Researchers want to develop a tool to predict how the disease will progress, so they will collect health data over time to see what factors affect outcomes.
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.